JP2015534985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534985A5 JP2015534985A5 JP2015538082A JP2015538082A JP2015534985A5 JP 2015534985 A5 JP2015534985 A5 JP 2015534985A5 JP 2015538082 A JP2015538082 A JP 2015538082A JP 2015538082 A JP2015538082 A JP 2015538082A JP 2015534985 A5 JP2015534985 A5 JP 2015534985A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- bioavailability
- salt
- copovidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 16
- 229940126062 Compound A Drugs 0.000 claims 14
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 14
- 239000003623 enhancer Substances 0.000 claims 8
- 229920001531 copovidone Polymers 0.000 claims 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000001556 precipitation Methods 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 239000012085 test solution Substances 0.000 claims 3
- -1 3-tert-butyl-5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -yl) -2-methoxyphenyl Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000845 uracil-1-yl group Chemical group [*]N1C(=O)N([H])C(=O)C([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261715766P | 2012-10-18 | 2012-10-18 | |
| US61/715,766 | 2012-10-18 | ||
| PCT/US2013/065760 WO2014063101A1 (en) | 2012-10-18 | 2013-10-18 | Formulations of pyrimidinedione derivative compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017242601A Division JP2018065858A (ja) | 2012-10-18 | 2017-12-19 | ピリミジンジオン誘導体化合物の製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534985A JP2015534985A (ja) | 2015-12-07 |
| JP2015534985A5 true JP2015534985A5 (enExample) | 2016-12-01 |
| JP6266635B2 JP6266635B2 (ja) | 2018-01-24 |
Family
ID=49554481
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538082A Expired - Fee Related JP6266635B2 (ja) | 2012-10-18 | 2013-10-18 | ピリミジンジオン誘導体化合物の製剤 |
| JP2017242601A Ceased JP2018065858A (ja) | 2012-10-18 | 2017-12-19 | ピリミジンジオン誘導体化合物の製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017242601A Ceased JP2018065858A (ja) | 2012-10-18 | 2017-12-19 | ピリミジンジオン誘導体化合物の製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9629841B2 (enExample) |
| EP (1) | EP2908808A1 (enExample) |
| JP (2) | JP6266635B2 (enExample) |
| CN (2) | CN109260207A (enExample) |
| AU (1) | AU2013330993B2 (enExample) |
| BR (1) | BR112015008927A2 (enExample) |
| CA (1) | CA2888883A1 (enExample) |
| EA (2) | EA028481B1 (enExample) |
| MX (1) | MX2015004973A (enExample) |
| SG (1) | SG11201503051QA (enExample) |
| WO (1) | WO2014063101A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| KR20220149744A (ko) * | 2020-03-05 | 2022-11-08 | 오리진 디스커버리 테크놀로지스 리미티드 | 키나제 억제제의 약학적 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4442257A1 (de) | 1994-11-28 | 1996-05-30 | Beate Dr Podschun | Sparsomycin |
| ATE349203T1 (de) | 1998-06-11 | 2007-01-15 | Pharmacia & Upjohn Co Llc | Delavirdin tablettenformulierung |
| KR100558239B1 (ko) | 1999-12-23 | 2006-03-10 | 화이자 프로덕츠 인크. | 증가된 약물 농도를 제공하는 제약학적 조성물 |
| GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
| US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| JP2008524239A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | ナノ粒子のタクロリムス製剤 |
| US20070082952A1 (en) * | 2005-10-06 | 2007-04-12 | Benjamin Eric J | Pharmaceutical compositions, methods of preparation thereof, and methods of treatment |
| PL2639226T3 (pl) * | 2007-09-17 | 2017-02-28 | Abbvie Bahamas Ltd. | Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania |
| AU2008302448B2 (en) | 2007-09-17 | 2014-11-06 | Abbvie Ireland Unlimited Company | Uracil or thymine derivative for treating hepatitis C |
| US20100166861A1 (en) * | 2008-12-29 | 2010-07-01 | Kelly Noel Lynch | Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone |
| EP2542075A4 (en) | 2010-03-01 | 2014-11-05 | Concert Pharmaceuticals Inc | Fluorouracil DERIVATIVES |
| DE112012003457T5 (de) * | 2011-10-21 | 2015-03-12 | Abbvie Inc. | Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV) |
-
2013
- 2013-10-18 US US14/058,071 patent/US9629841B2/en not_active Expired - Fee Related
- 2013-10-18 CN CN201811208736.2A patent/CN109260207A/zh active Pending
- 2013-10-18 AU AU2013330993A patent/AU2013330993B2/en not_active Ceased
- 2013-10-18 EP EP13789411.9A patent/EP2908808A1/en not_active Withdrawn
- 2013-10-18 WO PCT/US2013/065760 patent/WO2014063101A1/en not_active Ceased
- 2013-10-18 JP JP2015538082A patent/JP6266635B2/ja not_active Expired - Fee Related
- 2013-10-18 EA EA201590752A patent/EA028481B1/ru not_active IP Right Cessation
- 2013-10-18 EA EA201791354A patent/EA032913B1/ru not_active IP Right Cessation
- 2013-10-18 CN CN201380066499.XA patent/CN104853752B/zh not_active Expired - Fee Related
- 2013-10-18 SG SG11201503051QA patent/SG11201503051QA/en unknown
- 2013-10-18 MX MX2015004973A patent/MX2015004973A/es unknown
- 2013-10-18 CA CA2888883A patent/CA2888883A1/en not_active Abandoned
- 2013-10-18 BR BR112015008927A patent/BR112015008927A2/pt not_active IP Right Cessation
-
2017
- 2017-03-10 US US15/455,477 patent/US10201542B2/en active Active
- 2017-12-19 JP JP2017242601A patent/JP2018065858A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537899A5 (enExample) | ||
| TWI745349B (zh) | 一種含有ｊａｋ激酶抑制劑或其可藥用鹽的醫藥組成物 | |
| TWI660748B (zh) | 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液 | |
| JP2013519632A5 (enExample) | ||
| JP2011079859A5 (enExample) | ||
| RU2019134558A (ru) | Композиции и способы лечения анемии | |
| JP2013500977A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| CN116650500A (zh) | 治疗癌症的方法 | |
| TW201609091A (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物 | |
| JP2013522229A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| JP2015534985A5 (enExample) | ||
| JP2021520400A (ja) | エダラボン医薬組成物 | |
| JP2017517553A5 (enExample) | ||
| JP2018531273A5 (enExample) | ||
| JP2015500294A5 (enExample) | ||
| JP2018514564A5 (enExample) | ||
| TWI606826B (zh) | 艾拉莫德或其鹽之用途 | |
| JP2014533283A (ja) | ４−メチル−３−［［４−（３−ピリジニル）−２−ピリミジニル］アミノ］−ｎ−［５−（４−メチル−１ｈ−イミダゾール−１−イル）−３−（トリフルオロメチル）フェニル］ベンズアミドの即放性製剤 | |
| CN117412751A (zh) | 用于预防或治疗肺纤维化的药物制剂 | |
| Ruebsamen-Schaeff et al. | Different solid forms for optimizing route of administration of the herpes drug Pritelivir | |
| US20170128482A1 (en) | Modified release pharmaceutical compositions of sofosbuvir and ribavirin | |
| JP2022524819A (ja) | カプシド集合調節剤固体製剤 | |
| WO2015014737A1 (en) | Multilayer tablet formulations comprising tenofovir and entecavir |